Download PDF

1. Company Snapshot

1.a. Company Description

TherapeuticsMD, Inc.operates as a women's healthcare company in the United States.The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.


Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation.It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands.The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.


TherapeuticsMD, Inc.was founded in 2008 and is headquartered in Boca Raton, Florida.

Show Full description

1.b. Last Insights on TXMD

TherapeuticsMD's recent performance was positively driven by its robust product portfolio and strategic developments. The company's recent earnings release showcased its growth potential. Analysts have been scrutinizing the company's prospects, with a focus on its profitability and valuation. A share buyback initiative could be on the horizon, potentially reducing outstanding shares and increasing shareholder value. TherapeuticsMD's prospects are being evaluated against its peers, such as Journey Medical, amidst a competitive landscape in the medical industry. (Source: Analyst Ratings)

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Reviewing Journey Medical (NASDAQ:DERM) and TherapeuticsMD (NASDAQ:TXMD)

Oct -24

Source: defenseworld.net

Card image cap

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

Aug -26

Source: benzinga.com

Card image cap

TherapeuticsMD Announces First Quarter 2024 Financial Results

May -10

Source: businesswire.com

Card image cap

All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

Apr -14

Source: Zacks Investment Research

Card image cap

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

Jan -03

Source: businesswire.com

Card image cap

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

Jan -03

Source: businesswire.com

Card image cap

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

Dec -04

Source: businesswire.com

Card image cap

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

Dec -04

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.33%)

6. Segments

License

Expected Growth: 9.33%

The 9.33% growth is driven by increasing demand for women's healthcare products, TherapeuticsMD's strong brand recognition, and expanding distribution channels. Additionally, the license agreement provides access to a broader product portfolio, enhancing revenue potential. Furthermore, strategic partnerships and investments in R&D are expected to fuel future growth.

7. Detailed Products

Bijuva

Bijuva is a bio-identical hormone therapy (BHT) capsule for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

Imvexxy

Imvexxy is a vaginal insert for the treatment of moderate to severe dyspareunia (pain during sex) due to menopause.

Annovera

Annovera is a vaginal ring for the prevention of pregnancy.

8. TherapeuticsMD, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

TherapeuticsMD, Inc. operates in a highly competitive industry with many substitutes available, but the company's products have some level of differentiation, which reduces the threat of substitutes.

Bargaining Power Of Customers

TherapeuticsMD, Inc.'s customers have limited bargaining power due to the company's strong brand and product offerings, which reduces the bargaining power of customers.

Bargaining Power Of Suppliers

TherapeuticsMD, Inc. has a moderate level of dependence on its suppliers, but the company has implemented strategies to mitigate the bargaining power of suppliers.

Threat Of New Entrants

The pharmaceutical industry is highly regulated, and TherapeuticsMD, Inc. operates in a niche market, which makes it difficult for new entrants to enter the market, but the threat of new entrants is still high due to the attractiveness of the market.

Intensity Of Rivalry

TherapeuticsMD, Inc. operates in a highly competitive industry with many established players, which leads to a high level of rivalry among competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 21.47%
Debt Cost 3.95%
Equity Weight 78.53%
Equity Cost 9.25%
WACC 8.11%
Leverage 27.33%

11. Quality Control: TherapeuticsMD, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Eagle Pharma

A-Score: 5.0/10

Value: 10.0

Growth: 1.8

Quality: 8.3

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Organogenesis Holdings

A-Score: 4.6/10

Value: 8.4

Growth: 3.9

Quality: 5.5

Yield: 0.0

Momentum: 8.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Cyclo Therapeutics

A-Score: 3.8/10

Value: 8.0

Growth: 3.4

Quality: 5.0

Yield: 0.0

Momentum: 5.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Cumberland Pharmaceuticals

A-Score: 3.3/10

Value: 6.9

Growth: 2.3

Quality: 5.2

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
TherapeuticsMD

A-Score: 3.2/10

Value: 7.3

Growth: 4.8

Quality: 5.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Rockwell Medical

A-Score: 2.6/10

Value: 6.4

Growth: 4.2

Quality: 3.4

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.74$

Current Price

1.74$

Potential

-0.00%

Expected Cash-Flows